Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours.

Lowe KL, Cole D, Kenefeck R, OKelly I, Lepore M, Jakobsen BK.

Cancer Treat Rev. 2019 Jul;77:35-43. doi: 10.1016/j.ctrv.2019.06.001. Epub 2019 Jun 12. Review.

2.

TCR-induced alteration of primary MHC peptide anchor residue.

Madura F, Rizkallah PJ, Legut M, Holland CJ, Fuller A, Bulek A, Schauenburg AJ, Trimby A, Hopkins JR, Wells SA, Godkin A, Miles JJ, Sami M, Li Y, Liddy N, Jakobsen BK, Loveridge EJ, Cole DK, Sewell AK.

Eur J Immunol. 2019 Jul;49(7):1052-1066. doi: 10.1002/eji.201948085. Epub 2019 May 27.

3.

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

Harper J, Adams KJ, Bossi G, Wright DE, Stacey AR, Bedke N, Martinez-Hague R, Blat D, Humbert L, Buchanan H, Le Provost GS, Donnellan Z, Carreira RJ, Paston SJ, Weigand LU, Canestraro M, Sanderson JP, Botta Gordon-Smith S, Lowe KL, Rygiel KA, Powlesland AS, Vuidepot A, Hassan NJ, Cameron BJ, Jakobsen BK, Dukes J.

PLoS One. 2018 Oct 15;13(10):e0205491. doi: 10.1371/journal.pone.0205491. eCollection 2018.

4.

Fludarabine and neurotoxicity in engineered T-cell therapy.

Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G.

Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7.

PMID:
29789639
5.

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Boudousquie C, Bossi G, Hurst JM, Rygiel KA, Jakobsen BK, Hassan NJ.

Immunology. 2017 Nov;152(3):425-438. doi: 10.1111/imm.12779. Epub 2017 Aug 2.

6.

Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Ojiro K, Qu X, Cho H, Park JJ, Vuidepot A, Lissin N, Molloy PE, Bennett A, Jakobsen BK, Kaplan DE, Riley JL, Chang KM.

J Virol. 2017 Apr 28;91(10). pii: e02129-16. doi: 10.1128/JVI.02129-16. Print 2017 May 15.

7.

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Yang H, Buisson S, Bossi G, Wallace Z, Hancock G, So C, Ashfield R, Vuidepot A, Mahon T, Molloy P, Oates J, Paston SJ, Aleksic M, Hassan NJ, Jakobsen BK, Dorrell L.

Mol Ther. 2016 Nov;24(11):1913-1925. doi: 10.1038/mt.2016.114. Epub 2016 Jun 6.

8.

Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells.

Tan MP, Dolton GM, Gerry AB, Brewer JE, Bennett AD, Pumphrey NJ, Jakobsen BK, Sewell AK.

Clin Exp Immunol. 2017 Jan;187(1):124-137. doi: 10.1111/cei.12828. Epub 2016 Nov 14.

9.

Obituary.

Jakobsen BK, Dickmeiss E.

HLA. 2016 Jun;87(6):411-2. doi: 10.1111/tan.12818. No abstract available.

PMID:
27283134
10.

Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies.

Hickman ES, Lomax ME, Jakobsen BK.

J Biomol Screen. 2016 Sep;21(8):769-85. doi: 10.1177/1087057116637837. Epub 2016 Mar 18. Review.

PMID:
26993321
11.

Cholesteryl esters stabilize human CD1c conformations for recognition by self-reactive T cells.

Mansour S, Tocheva AS, Cave-Ayland C, Machelett MM, Sander B, Lissin NM, Molloy PE, Baird MS, Stübs G, Schröder NW, Schumann RR, Rademann J, Postle AD, Jakobsen BK, Marshall BG, Gosain R, Elkington PT, Elliott T, Skylaris CK, Essex JW, Tews I, Gadola SD.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1266-75. doi: 10.1073/pnas.1519246113. Epub 2016 Feb 16.

12.

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, Le Provost GS, Todorov P, Baston E, Hickman E, Mahon T, Hassan N, Vuidepot A, Sami M, Cole DK, Jakobsen BK.

Sci Rep. 2016 Jan 13;6:18851. doi: 10.1038/srep18851.

13.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

14.

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ, Jakobsen BK, Jorritsma A, Blank CU, Schumacher TN, Haanen JB.

Mol Ther. 2015 Sep;23(9):1541-50. doi: 10.1038/mt.2015.60. Epub 2015 Apr 21.

15.

ImmTACs for targeted cancer therapy: Why, what, how, and which.

Oates J, Hassan NJ, Jakobsen BK.

Mol Immunol. 2015 Oct;67(2 Pt A):67-74. doi: 10.1016/j.molimm.2015.01.024. Epub 2015 Feb 21. Review.

PMID:
25708206
16.

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.

Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, Pumphrey NJ, Jakobsen BK, Price DA, Ladell K, Sewell AK.

Clin Exp Immunol. 2015 May;180(2):255-70. doi: 10.1111/cei.12570.

17.

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.

Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ.

Cancer Immunol Immunother. 2014 May;63(5):437-48. doi: 10.1007/s00262-014-1525-z. Epub 2014 Feb 15.

PMID:
24531387
18.

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.

Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan NJ, Jakobsen BK.

Oncoimmunology. 2013 Nov 1;2(11):e26840. Epub 2013 Oct 21.

19.

T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions.

Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, Bulek AM, Fuller A, Akpovwa HJ, Pymm PG, Liddy N, Sami M, Li Y, Rizkallah PJ, Jakobsen BK, Sewell AK.

J Biol Chem. 2014 Jan 10;289(2):628-38. doi: 10.1074/jbc.M113.522110. Epub 2013 Nov 6.

20.

The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.

Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pumphrey N, Rödström K, Lindkvist-Petersson K, Björk P.

PLoS One. 2013 Oct 23;8(10):e79082. doi: 10.1371/journal.pone.0079082. eCollection 2013.

21.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.

Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.

22.

Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.

Cole DK, Sami M, Scott DR, Rizkallah PJ, Borbulevych OY, Todorov PT, Moysey RK, Jakobsen BK, Boulter JM, Baker BM, Yi Li.

Front Immunol. 2013 Jun 26;4:168. doi: 10.3389/fimmu.2013.00168. eCollection 2013.

23.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH.

Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.

24.

T-cell receptor specificity maintained by altered thermodynamics.

Madura F, Rizkallah PJ, Miles KM, Holland CJ, Bulek AM, Fuller A, Schauenburg AJ, Miles JJ, Liddy N, Sami M, Li Y, Hossain M, Baker BM, Jakobsen BK, Sewell AK, Cole DK.

J Biol Chem. 2013 Jun 28;288(26):18766-75. doi: 10.1074/jbc.M113.464560. Epub 2013 May 22.

25.

ImmTACs: Novel bi-specific agents for targeted cancer therapy.

Oates J, Jakobsen BK.

Oncoimmunology. 2013 Feb 1;2(2):e22891.

26.

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK.

Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22.

27.

Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies.

Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK.

Eur J Immunol. 2012 Dec;42(12):3174-9. doi: 10.1002/eji.201242606. Epub 2012 Oct 16.

28.

Monoclonal TCR-redirected tumor cell killing.

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK.

Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764.

PMID:
22561687
29.

TCR affinity and specificity requirements for human regulatory T-cell function.

Plesa G, Zheng L, Medvec A, Wilson CB, Robles-Oteiza C, Liddy N, Bennett AD, Gavarret J, Vuidepot A, Zhao Y, Blazar BR, Jakobsen BK, Riley JL.

Blood. 2012 Apr 12;119(15):3420-30. doi: 10.1182/blood-2011-09-377051. Epub 2012 Feb 7.

30.

Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.

Bulek AM, Cole DK, Skowera A, Dolton G, Gras S, Madura F, Fuller A, Miles JJ, Gostick E, Price DA, Drijfhout JW, Knight RR, Huang GC, Lissin N, Molloy PE, Wooldridge L, Jakobsen BK, Rossjohn J, Peakman M, Rizkallah PJ, Sewell AK.

Nat Immunol. 2012 Jan 15;13(3):283-9. doi: 10.1038/ni.2206.

31.

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ.

Blood. 2011 Jul 14;118(2):319-29. doi: 10.1182/blood-2010-12-326736. Epub 2011 May 23.

32.

The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.

Hansen BE, Nielsen CH, Madsen HO, Ryder LP, Jakobsen BK, Svejgaard A.

Tissue Antigens. 2011 Mar;77(3):229-34. doi: 10.1111/j.1399-0039.2010.01614.x.

PMID:
21299528
33.

High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation.

Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, Johnson AD, Brewer JE, Ashfield R, Lissin NM, Jakobsen BK.

Protein Cell. 2010 Dec;1(12):1118-27. doi: 10.1007/s13238-010-0144-5. Epub 2011 Jan 8.

34.

Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop.

Matulis G, Sanderson JP, Lissin NM, Asparuhova MB, Bommineni GR, Schümperli D, Schmidt RR, Villiger PM, Jakobsen BK, Gadola SD.

PLoS Biol. 2010 Jun 22;8(6):e1000402. doi: 10.1371/journal.pbio.1000402.

35.

[Allogeneic haematopoietic cell transplantation with nonmyeloablative conditioning in Denmark].

Masmas TN, Kornblit B, Sengeløv H, Madsen HO, Jakobsen BK, Olesen G, Vindeløv LL.

Ugeskr Laeger. 2010 May 10;172(19):1456. Danish. No abstract available.

PMID:
20480957
36.

Allogeneic haematopoietic cell transplantation with nonmyeloablative conditioning in Denmark.

Masmas TN, Kornblit B, Sengeløv H, Madsen HO, Jakobsen BK, Olesen G, Vindeløv LL.

Dan Med Bull. 2010 May;57(5):A4146.

PMID:
20441714
37.

Production of a soluble disulfide bond-linked TCR in the cytoplasm of Escherichia coli trxB gor mutants.

Liddy N, Molloy PE, Bennett AD, Boulter JM, Jakobsen BK, Li Y.

Mol Biotechnol. 2010 Jun;45(2):140-9. doi: 10.1007/s12033-010-9250-0.

PMID:
20143183
38.

Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, Gao GF, Jakobsen BK, Sewell AK.

J Biol Chem. 2009 Oct 2;284(40):27281-9. doi: 10.1074/jbc.M109.022509. Epub 2009 Jul 15.

39.

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor.

Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL.

Nat Med. 2008 Dec;14(12):1390-5. doi: 10.1038/nm.1779. Epub 2008 Nov 9.

40.

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA.

J Immunol. 2008 May 1;180(9):6116-31.

41.

T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding.

Cole DK, Dunn SM, Sami M, Boulter JM, Jakobsen BK, Sewell AK.

Mol Immunol. 2008 May;45(9):2700-9. doi: 10.1016/j.molimm.2007.12.009. Epub 2008 Feb 19.

PMID:
18243322
42.

High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.

Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, Li Y, Molloy PE, Dunn SM, Jakobsen BK, Rosenberg SA, Morgan RA.

J Immunol. 2007 Nov 1;179(9):5845-54.

43.

Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex.

Yuan F, Georgiou T, Hillon T, Gostick E, Price DA, Sewell AK, Moysey R, Gavarret J, Vuidepot A, Sami M, Bell JI, Gao GF, Rizkallah PJ, Jakobsen BK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Sep 1;63(Pt 9):758-60. Epub 2007 Aug 25.

44.

Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry.

Sami M, Rizkallah PJ, Dunn S, Molloy P, Moysey R, Vuidepot A, Baston E, Todorov P, Li Y, Gao F, Boulter JM, Jakobsen BK.

Protein Eng Des Sel. 2007 Aug;20(8):397-403. Epub 2007 Jul 20.

PMID:
17644531
45.

The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.

Purbhoo MA, Li Y, Sutton DH, Brewer JE, Gostick E, Bossi G, Laugel B, Moysey R, Baston E, Liddy N, Cameron B, Bennett AD, Ashfield R, Milicic A, Price DA, Classon BJ, Sewell AK, Jakobsen BK.

Mol Cancer Ther. 2007 Jul;6(7):2081-91.

46.

Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.

Hansen BE, Rasmussen AH, Jakobsen BK, Ryder LP, Svejgaard A.

Tissue Antigens. 2007 Jul;70(1):42-52.

PMID:
17559580
47.

Human TCR-binding affinity is governed by MHC class restriction.

Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK.

J Immunol. 2007 May 1;178(9):5727-34.

48.

Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor.

Cole DK, Rizkallah PJ, Boulter JM, Sami M, Vuidepot AL, Glick M, Gao F, Bell JI, Jakobsen BK, Gao GF.

Proteins. 2007 Apr 1;67(1):65-74.

PMID:
17243170
49.

Making high-affinity T-cell receptors: a new class of targeted therapeutics.

Ashfield R, Jakobsen BK.

IDrugs. 2006 Aug;9(8):554-9. Review.

PMID:
16871464
50.

Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.

Purbhoo MA, Sutton DH, Brewer JE, Mullings RE, Hill ME, Mahon TM, Karbach J, Jäger E, Cameron BJ, Lissin N, Vyas P, Chen JL, Cerundolo V, Jakobsen BK.

J Immunol. 2006 Jun 15;176(12):7308-16.

Supplemental Content

Loading ...
Support Center